GILD vs ARGX vs MRNA Stock Comparison

Gilead Sciences, Argenx Se and Moderna Prices as of Nov 13, 2026 Peers: Industry group
GILD Gilead Sciences, Inc.
$168.08 +9.5% 1M +34.2% 1Y
Market cap
$207.56B
P/E
–
Revenue (TTM)
$30.99B
Div. yield
–
Biotechnology Healthcare
3 wins
ARGX Argenx Se
$960.04 +17.3% 1M +7.7% 1Y
Market cap
$58.18B
P/E
31.0x
Revenue (TTM)
$5.82B
Div. yield
–
Biotechnology Healthcare
4 wins
MRNA Moderna, Inc.
$223.37 -1.3% 1M +794.9% 1Y
Market cap
$86.12B
P/E
–
Revenue (TTM)
$2.53B
Div. yield
–
Biotechnology Healthcare
2 wins

Head to Head

9 decided of 12

Argenx Se leads on 4 of the 12 questions below (Argenx Se 4, Gilead Sciences 3, Moderna 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionGILDARGXMRNALeader
Larger companyMarket capitalisation $207.56B $58.18B $86.12B GILD
Cheaper on earningsLower P/E, profitable companies only -53.7x 31.0x -30.9x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS — 32.8x — –
Faster revenue growthRevenue growth, trailing twelve months +6.5% +61.5% +13.1% ARGX
More profitableNet margin, trailing twelve months -12.5% 32.3% -110.5% ARGX
Better return on capitalReturn on invested capital -6.1% — -39.6% GILD
Less leveragedLower net debt / EBITDA 43.8x — 1.7x MRNA
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +34.2% +7.7% +794.9% MRNA
Better 5-year returnAnnualised price return, 5 years +20.0%/yr +25.4%/yr -0.7%/yr ARGX
Less volatileAnnualised volatility, 1 year 27.5% 37.7% 130.6% GILD
Higher overall scoreMean of the five percentile scores vs peers 61/100 92/100 60/100 ARGX

Percentile Scorecard

GILDARGXMRNA

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisGILDARGXMRNA
Valuation 89 #71 of 660 82 #122 of 660 69 #208 of 660
Growth 34 #408 of 619 96 #27 of 619 45 #344 of 619
Profitability 85 #91 of 595 99 #9 of 595 60 #239 of 595
Financial Health 22 #530 of 683 – 52 #330 of 683
Shareholder Returns 75 #116 of 459 – 76 #112 of 459
Overall 61 92 60
  • GILD ranked among 695 companies in Pharmaceuticals and Biotechnology
  • ARGX ranked among 695 companies in Pharmaceuticals and Biotechnology
  • MRNA ranked among 695 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodGILDARGXMRNASPY
1 month +9.5%+17.3%-1.3% -2.0%
3 months +21.5%+12.8%+252.8% -2.8%
6 months +29.7%+20.1%+355.5% +2.0%
Year to date +36.9%+14.2%+657.4% +10.6%
1 year +34.2%+7.7%+794.9% +12.2%
3 years +124.9%+96.0%+201.4% +68.1%
3 years, per year +31.1%+25.2%+44.5% +18.9%
5 years +149.1%+210.1%-3.4% +61.4%
5 years, per year +20.0%+25.4%-0.7% +10.1%
10 years +119.9%—— +248.5%
10 years, per year +8.2%—— +13.3%

Risk

MeasureGILDARGXMRNASPY
Volatility, 1Y 27.5%37.7%130.6% 13.6%
Downside volatility, 1Y 24.0%35.2%79.2% 13.9%
Beta vs S&P 500, 1Y 0.390.542.26 1.00
Return / volatility, 1Y 1.250.206.09 0.90
Max drawdown, 5Y -29.4%-38.2%-93.9% -25.4%
From 52-week high -3.7%-9.3%-16.9% -3.2%
52-week high $174.48$1,058.90$268.86 $779.14
52-week low $118.30$663.93$22.36 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleGILDARGXMRNA
P/E now vs peer median -54.0xmedian 17.0x 31.4xmedian 17.0x -32.1xmedian 17.0x
P/S now vs peer median 6.7xmedian 8.4x 10.2xmedian 8.4x 35.7xmedian 8.4x
EV/EBITDA now vs peer median 505.3xmedian 14.6x —median 14.6x -32.0xmedian 14.6x
P/FCF now vs peer median 15.1xmedian 19.0x —median 19.0x -45.8xmedian 19.0x
P/B now vs peer median 16.0xmedian 2.0x —median 2.0x 13.2xmedian 2.0x
PEG now vs peer median 1.40median 0.43 0.30median 0.43 -3.01median 0.43

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsGILDARGXMRNA
Revenue $30.99B $5.82B $2.53B
Gross profit $24.77B $5.24B $707.00M
Operating income -$2.36B $1.74B -$2.93B
Net income -$3.86B $1.88B -$2.79B
Free cash flow $13.78B – -$1.97B
R&D $6.33B $1.80B $2.66B
EPS (diluted) $-3.09 $28.43 $-6.49
Cash & equivalents $6.44B – $1.20B
Total debt $26.23B – $591.00M
Shares (diluted) 1.25B 66.03M 430.00M
Enterprise value $182.67B $58.18B $64.81B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricGILDARGXMRNA
P/E -54.0x 31.4x -32.1x
P/FCF 15.1x – -45.8x
P/Operating cash flow 14.4x – -50.6x
P/S 6.7x 10.2x 35.7x
P/B 16.0x – 13.2x
P/Tangible book -543.2x – 13.2x
EV/EBITDA 505.3x – -32.0x
EV/EBIT -96.7x 34.1x -29.2x
EV/Revenue 7.4x 10.2x 33.9x
EV/FCF 16.6x – -43.5x
EV/Operating cash flow 15.8x – -48.0x
PEG (3Y EPS CAGR) 1.40 0.30 -3.01

Growth

14 metrics
MetricGILDARGXMRNA
Revenue growth (1Y) 6.5% 61.5% 13.1%
Revenue CAGR (3Y) 4.2% 80.5% -34.8%
Gross profit growth (1Y) 8.2% 62.2% -34.4%
Gross profit CAGR (3Y) 4.7% 80.0% -41.0%
Operating income growth (1Y) -122.5% 120.6% 15.4%
Operating income CAGR (3Y) -31.7% 85.1% -3.2%
Net income growth (1Y) -147.6% 22.5% 10.5%
Net income CAGR (3Y) -38.5% 115.5% 7.0%
EPS growth (1Y) -147.7% 20.9% 18.8%
EPS CAGR (3Y) -38.6% 104.8% 10.7%
Operating cash flow growth (1Y) 49.8% – 9.8%
Operating cash flow CAGR (3Y) 19.9% – 4.9%
Free cash flow growth (1Y) 50.4% – 25.7%
Free cash flow CAGR (3Y) 20.6% – 9.5%

Profitability

14 metrics
MetricGILDARGXMRNA
Gross margin 79.9% 90.0% 28.0%
EBITDA margin 1.5% – -105.9%
Operating margin -7.6% 29.9% -116.0%
Pretax margin -8.2% 32.6% -108.1%
Net margin -12.5% 32.3% -110.5%
FCF margin 44.5% – -78.0%
Operating cash flow margin 46.7% – -70.7%
Return on equity -31.2% – -41.0%
Return on assets -7.7% – -22.8%
Return on invested capital -6.1% – -39.6%
Return on capital employed -6.2% – -28.8%
Asset turnover 0.6x – 0.2x
Cash conversion (OCF / net income) -3.7x – 0.6x
Stock comp / revenue 2.9% – 18.4%

Financial Health

11 metrics
MetricGILDARGXMRNA
Debt / assets 51.0% – 4.4%
Debt / equity 2.0x – 0.1x
Net debt / EBITDA 43.8x – 1.7x
Debt / FCF 1.9x – -0.3x
Liabilities / assets 74.6% – 49.2%
Equity / assets 25.4% – 50.8%
Interest coverage -2.3x 10,120x –
Current ratio 1.4x – 3.6x
Quick ratio 1.0x – 3.2x
Cash ratio 0.5x – 2.5x
Altman Z-score 3.90 – 8.66

Shareholder Returns

7 metrics
MetricGILDARGXMRNA
Dividend yield 1.9% – –
Net buyback yield 0.5% – -0.2%
Shareholder yield 2.5% – -0.2%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusGILDARGXMRNA
Forward P/E – 32.8xFY2026 –
EPS, next fiscal year $-0.84FY2026 $29.27FY2026 $-7.17FY2026
EPS growth, next FY -110.3%FY2026 +49.6%FY2026 –
EPS growth, the year after – +32.0% –
Revenue, next fiscal year $29.15BFY2026 $6.16BFY2026 $2.22BFY2026
Revenue growth, next FY -1.0%FY2026 +44.9%FY2026 +14.6%FY2026
Revenue growth, the year after +18.3% +24.0% +25.8%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersGILDARGXMRNA
Held by institutions 89.6% 46.1% 80.2%
Institutions holding 2,293 506 787
Change in shares held, QoQ +5.1% -2.0% +3.4%
Institutions buying 1,113 263 404
Institutions selling 853 162 239
Buyers to sellers 1.30 1.62 1.69

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

GILDARGXMRNA
GILD 1.00 0.26 0.26
ARGX 0.26 1.00 0.19
MRNA 0.26 0.19 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, GILD, ARGX and MRNA?

Gilead Sciences (GILD) is the largest by market capitalisation: Gilead Sciences (GILD) $207.56B, Argenx Se (ARGX) $58.18B, Moderna (MRNA) $86.12B.

Which company is growing faster?

Argenx Se (ARGX) grew revenue fastest over the trailing twelve months: Gilead Sciences (GILD) +6.5%, Argenx Se (ARGX) +61.5%, Moderna (MRNA) +13.1%.

Which company is more profitable?

Argenx Se (ARGX) has the highest net margin (Gilead Sciences (GILD) -12.5%, Argenx Se (ARGX) 32.3%, Moderna (MRNA) -110.5%). On return on invested capital, Gilead Sciences (GILD) leads (Gilead Sciences (GILD) -6.1%, Moderna (MRNA) -39.6%).

Which stock has performed better?

Over the past year Moderna (MRNA) returned the most: Gilead Sciences (GILD) +34.2%, Argenx Se (ARGX) +7.7%, Moderna (MRNA) +794.9%. Over five years, Argenx Se (ARGX) compounded fastest (Gilead Sciences (GILD) +20.0%/yr, Argenx Se (ARGX) +25.4%/yr, Moderna (MRNA) -0.7%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Gilead Sciences (GILD) has been the steadiest (Gilead Sciences (GILD) 27.5%, Argenx Se (ARGX) 37.7%, Moderna (MRNA) 130.6%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, GILD, ARGX and MRNA?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Argenx Se (ARGX) leads on 4. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.